Clinical Trials Service

Home Team Members Patient Information Clinical Trials Basic Research Fellowship Program Images of Omaha Contact Us: Division of Allergy and Immunology CreightonUniversity 601 North 30th Street, Suite 3M-100 Omaha,NE 68131 Ph.402.280.5975 Fx.402.280.5961 Email

The Center is conducting the following new and exciting studies. If you or someone you know is eligible and interested, we would love to hear from you.  Please call (402) 280-5975. Patient Demographics       The Omaha area has a population of over 750,000. The Division’s clinical research patient database alone is currently comprised of over 5,000 patients and is constantly growing through the various recruitment efforts including media advertising, health fair involvement as well as volunteer work. Our diverse patient population is drawn not only from the Omaha metropolitan area (urban/suburban), but also from the surrounding communities in Eastern Nebraska and Western Iowa (rural). Areas of Research Acute and chronic otitis media Acute and chronic urticaria Acute sinusitis Allergic asthma Allergic bronchopulmonary aspergillosis Allergic conjunctivitis Angioedema Asthma in pregnancy B cell immunodeficiencies Bronchitis Common variable immunodeficiency Contact dermatitis Drug allergy Exercise induced asthma Food allergy and food hypersensitivity Immunizations and immunoprophylaxis Insect allergy Latex allergy Management of immunotherapy Non-allergic asthma Nasal polyposis  Perennial allergic rhinitis  Seasonal allergic rhinitis  Status asthmaticus  T-cell immunodeficiencies  Vasomotor rhinitis Urticaria      The Division of Allergy and Immunology has a three bed inpatient unit suitable for Phase I and Phase II studies.  The Division conducts first-in-man studies and has several model systems for proof of concept trials for allergic and respiratory diseases. In addition, the basic research laboratories of the Division are capable of assisting in clinical trials with the measurement of biomarkers and mechanistic assays.  Procedures and Equipment Available Acoustic Rhinometry Aeroallergen challenge Exercise challenge Hypertonic Saline challenge Methacholine challenge Bronchoprovocation Challenges Biomarker Assays (Interleukins/Cytokines, Leukotrienes, Histamine, Tryptase, ECP)                  Digital Electrocardiography Machine Full Pulmonary Function Laboratory Immediate and Delayed Hypersensitivity Skin Testing Immunotherapy Inpatient Beds Nasal Allergen Challenges and Lavage Nitric Oxide Measurements (oral/nasal) Oral Desensitization Parenteral Therapy Facilities Phlebotomy Pollen Collection Radiology Suite for Routine X-Rays, MRIs ,CTs, Nuclear Studies Remote Data Entry Capabilities Spirometry Sputum Induction Treadmill Exercise Testing Investigators Thomas B. Casale, M.D. Professor of Medicine and Medical Microbiology & Immunology; Chief, Division of Allergy & Immunology Bio Robert G. Townley, M.D. Professor of Medicine and Medical Microbiology & Immunology Bio Againdra K. Bewtra, M.B.B.S. Associate Professor of Medicine & Biomedical SciencesBio Jeffrey R. Stokes, M.D. Associate Professor of Medicine, Fellowship Program Director, Fellowship Program  Bio Russell J. Hopp, D.O. Professor of Pediatrics and Medicine; Chief, Division of Pediatric Allergy & Clinical ImmunologyBio  Staff Patrick De Nier:  Operations Manager Tony Tony Romero, MS:  Budget, Contracts, & Regulatory Documents Dian Jean Kessler, RN, BSN, CCRC:  Research Coordinator Lori   Lori Mahon, RN, BSN,CCRC: Research Coordinator Jani  Janie Misfieldt, MA, CCRC:  Research Coordinator Jean Danial Avant, LPN, MA:  Research Coordinator Current Clinical Trials Randomized, double-blind, placebo-controlled, dose-response, cross-over study to evaluate the effect of nasal carbon dioxide on nasal congestion via acoustic rhinometry in subject with perennial allergic rhinitis. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis. Phase 1B randomized, placebo-controlled clinical trial to study the safety and bronchodilatory effect of MK-0467 in patients with chronic asthma. Phase 2a, randomized, double-blind, double-dummy, placebo and active controlled, 5-way crossover study to assess the bronchodilatory action, safety, toleration and pharmacokinetics of single oral doses of PF-04191834 in asthmatic patients. Phase 1B Placebo-Controlled, Four-way Crossover Study to Determine the Effects of an H3 Receptor Antagonist -PF-03654756  on Congestion Following a Nasal Allergen Challenge in Subjects with Seasonal Allergic Rhinitis. A multicenter, randomized study starting with a 4-week, 2-way crossover double-blind treatment phase comparing the efficacy and safety of Combivent® CFC MDI to albuterol HFA MDI followed by a 4-week open label Combivent Respimat® treatment phase. Randomized, double-blind, placebo-controlled, multi-center, phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from grass pollen rhinoconjunctivitis. Phase IIa randomized double-blind placebo-controlled dose-escalating study to evaluate the safety and effect on exercise challenge testing of multiple fixed subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody in adults with stable asthma and exercise-induced bronchoconstriction A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older withPerennial Allergic Rhinitis Efficacy and Safety Study to Compare CFC MDI to Albuterol HFA followed by Combivent Repimat Treatment in Moderate to Severe Asthmatics, 19 years and older. Effects of Rosiglitazone on Airway Hyperreactivity in Asthmatics, Age 19 and older Exhaled Breath Condensate and Nitric Oxide: Non-Invasive Evaluation of Lung Disease after Treatment with Xolair in subjects with Allergic Asthma, 12 years and older.

Home| Team Members | Patient Information |
Current Clinical Trials | Fellowship Program